Table 1.
Baseline Characteristics of CAD Patients Stratified According to F11R-SNV-rs2774276 and to F11R-SNV-rs790056 Major Allele Carriers vs HCs of Minor Allele (Recessive Genetic Model)
| Carriers of Major Allele | HC of Minor Allele | P Value | |
|---|---|---|---|
| F11R-SNV-rs2774276 | |||
| n | 777 | 56 | |
| Age, y | 68.4 ± 11.6 | 70.0 ± 10.0 | 0.309 |
| Male | 549 (70.7) | 41 (73.2) | 0.716 |
| LVEF, % | 51.0 ± 10.7 | 52.0 ± 10.5 | 0.528 |
| Risk factors | |||
| Arterial hypertension | 649 (83.5) | 45 (80.4) | 0.926 |
| Hyperlipidemia | 454 (58.4) | 30 (53.6) | 0.621 |
| Diabetes mellitus type II | 257 (33.1) | 16 (28.6) | 0.593 |
| Smoking | 319 (41.1) | 20 (35.7) | 0.525 |
| Medication on admission | |||
| ASA | 430 (55.3) | 32 (57.1) | 0.850 |
| Clopidogrel | 94 (12.1) | 9 (16.1) | 0.400 |
| Prasugrel | 15 (1.9) | 2 (3.6) | 0.418 |
| Ticagrelor | 35 (4.5) | 2 (3.6) | 0.732 |
| ACE inhibitors | 332 (42.7) | 24 (42.9) | 0.983 |
| AT-1 antagonists | 139 (17.9) | 12 (21.4) | 0.522 |
| Calcium-channel blockers | 154 (19.8) | 14 (25.0) | 0.364 |
| Beta-blockers | 442 (56.9) | 31 (55.4) | 0.782 |
| Statins | 367 (47.2) | 30 (53.6) | 0.383 |
| Reason of admission, CCS vs ACS | |||
| ACS | 383 (49.3) | 28 (50.0) | 0.918 |
| Type of coronary intervention | |||
| PCI | 658 (84.7) | 50 (89.3) | 0.352 |
| CABG | 8 (1.0) | 0 (0.0) | 0.445 |
| None | 111 (14.3) | 6 (10.7) | 0.364 |
| Medication at discharge | |||
| ASA | 733 (94.3) | 52 (92.9) | 0.323 |
| Clopidogrel | 406 (52.3) | 30 (53.6) | 0.934 |
| Prasugrel | 120 (15.4) | 10 (17.9) | 0.664 |
| Ticagrelor | 145 (18.7) | 12 (21.4) | 0.646 |
| Simvastatin | 591 (76.1) | 46 (82.1) | 0.388 |
| Atorvastatin | 38 (4.8) | 2 (3.6) | 0.641 |
| Rosuvastatin | 24 (3.1) | 1 (1.8) | 0.571 |
| Pravastatin | 2 (0.3) | 1 (1.8) | 0.068 |
| Fluvastatin | 27 (3.5) | 2 (3.6) | 0.985 |
| Lovastatin | 1 (0.1) | 0 (0.0) | 0.787 |
| F11R-SNV- rs790056 | |||
| n | 791 | 40 | |
| Age, y | 68.4 ± 11.6 | 70.4 ± 10.2 | 0.294 |
| Male | 562 (71.0) | 28 (70.0) | 0.857 |
| LVEF, % | 50.9 ± 10.7 | 53.9 ± 10.0 | 0.092 |
| Risk factors | |||
| Arterial hypertension | 656 (82.9) | 35 (87.5) | 0.102 |
| Hyperlipidemia | 458 (57.9) | 24 (60.0) | 0.514 |
| Diabetes mellitus type II | 260 (32.9) | 12 (30.0) | 0.888 |
| Smoking | 324 (41.0) | 14 (35.0) | 0.619 |
| Medication on admission | |||
| ASA | 436 (55.1) | 24 (60.0) | 0.586 |
| Clopidogrel | 96 (12.1) | 7 (17.5) | 0.329 |
| Prasugrel | 17 (2.1) | 0 (0.0) | 0.346 |
| Ticagrelor | 35 (4.4) | 2 (5.0) | 0.875 |
| ACE inhibitors | 338 (42.7) | 17 (42.5) | 0.950 |
| AT-1 antagonists | 141 (17.8) | 10 (25.0) | 0.260 |
| Calcium-channel blockers | 159 (20.1) | 9 (22.5) | 0.728 |
| Beta-blockers | 450 (56.9) | 22 (55.0) | 0.779 |
| Statins | 373 (47.2) | 23 (57.5) | 0.215 |
| Reason of admission, CCS vs ACS | |||
| ACS | 392 (49.6) | 17 (42.5) | 0.384 |
| Type of coronary intervention | |||
| PCI | 671 (84.8) | 35 (87.5) | 0.645 |
| CABG | 8 (1.0) | 0 (0.0) | 0.523 |
| None | 112 (14.2) | 5 (12.5) | 0.768 |
| Medication at discharge | |||
| ASA | 746 (94.3) | 37 (92.5) | 0.351 |
| Clopidogrel | 413 (52.2) | 23 (57.5) | 0.574 |
| Prasugrel | 124 (15.7) | 6 (15.0) | 0.880 |
| Ticagrelor | 147 (18.6) | 8 (20.0) | 0.856 |
| Simvastatin | 603 (76.2) | 32 (72.5) | 0.691 |
| Atorvastatin | 37 (4.7) | 3 (7.5) | 0.430 |
| Rosuvastatin | 24 (3.0) | 1 (2.5) | 0.836 |
| Pravastatin | 3 (0.4) | 0 (0.0) | 0.694 |
| Fluvastatin | 28 (3.5) | 1 (2.5) | 0.716 |
| Lovastatin | 1 (0.1) | 0 (0.0) | 0.821 |
Values are mean ± SD or n (%).
ACE = angiotensin-converting enzyme; ASA = aspirin; ACS = acute coronary syndrome; CAD = coronary artery disease; CCS = chronic coronary syndrome; CE = combined endpoint; HC = homozygous carriers; JAM-A = junctional adhesion molecule-A; SNV = single nucleotide variation